FSHR and ovarian cancer: We have previously reported a targeted delivery system for paclitaxel and RNA interference (RNAi) drugs of growth-regulated oncogene α (gro-α) using FSHR-binding fragments as targeting moieties, which promoted the uptake of drugs by FSHR-expressing ovarian cancer cells (Zhang et al., 2009; Hong et al., 2013; Hong et al., 2018).